Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the guidance submitted to medical professions on the prescription of semaglutide on the availability of that drug for people suffering from type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients with type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking with pharmaceutical companies to increase the supply of semaglutide.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate she has made of the number of elective surgeries cancelled in the last 12 months.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Official NHS England statistics show that between September 2023 and September 2024 (latest National Health Service published data) the total number of elective surgeries cancelled in England for non-clinical reasons was 76,021. Some common non-clinical reasons for cancellations by the hospital include ward beds being unavailable, surgeon or theatre staff being unavailable, or emergency cases needing the theatre.
Further information is available at the following link:
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help prepare the NHS for winter 2023-24.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Winter planning for the National Health Service started earlier this year than in previous years. The urgent and emergency care recovery plan was published in January 2023 which included £1 billion of dedicated funding to support capacity. In July 2023, NHS England wrote to integrated care boards, trusts and primary care networks to set out a national approach to 2023/24 winter planning and the key steps to be taken across all parts of the system to meet the challenges expected from winter pressures.